To identify novel therapeutic targets in Acute Myeloid Leukemia (AML), we chemically interrogated 200 sequenced primary specimens. We identified Mubritinib, a known ERBB2 inhibitor, as a strong in vit
Acute myeloid leukemia (AML) is a type of heterogeneous and fatal hematopoietic malignancy. The ten-eleven translocation (TET) mediated DNA demethylation is known to be critically associated with AML
The expression of Eukaryotic translation initiation factor 2 subunit 3 (EIF2S3/eIF2γ) in patients with non-small cell lung cancer and colorectal cancer is lower than that in healthy people, but its fu
This zip package includes all the raw data involving in the article "Key Imidazolyl Groups That Induce Phenylalanine Flipping Enhance the Efficacy of Oral BRD9 Inhibitors for AML Treatment"submitted t
Supplementary Table from Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
